NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

摘要: Novexel is developing the novel, orally active, semisynthetic streptogramin NXL-103, which has potential therapeutic application in treatment of community-acquired pneumonia, community- or hospital-acquired MRSA, vancomycin-resistant enterococcus, and acute bacterial skin soft tissue infections. NXL-103 a combination A:streptogramin B components, initially developed 70:30 dose ratio. In multiple vitro studies, demonstrated potent activity against different types bacteria, such as Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, pyogenes, Enterococcus faecium, faecalis, Haemophilus influenzae parainfluenzae. was not affected by resistance profiles bacteria other commonly used antibiotics. phase I clinical trials, achieved bactericidal levels plasma generally well tolerated, with side effects primarily on gastrointestinal system. The first II trial conducted to evaluate efficacy pneumonia revealed that compound comparable amoxicillin. promise become an important agent complex infections, pending further development.